New insights into the suppression of inflammation and lipid accumulation by JAZF1

Atherosclerosis is one of the leading causes of disease and death worldwide. The identification of new therapeutic targets and agents is critical. JAZF1 is expressed in many tissues and is found at particularly high levels in adipose tissue (AT). JAZF1 suppresses inflammation (including IL-1β, IL-4,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wujun, Zhong, Yingjie, Yuan, Yang, Zhu, Meng, Hu, Wenchao, Liu, Ning, Xing, Dongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404878/
https://www.ncbi.nlm.nih.gov/pubmed/37554201
http://dx.doi.org/10.1016/j.gendis.2022.10.029
_version_ 1785085400014913536
author Chen, Wujun
Zhong, Yingjie
Yuan, Yang
Zhu, Meng
Hu, Wenchao
Liu, Ning
Xing, Dongming
author_facet Chen, Wujun
Zhong, Yingjie
Yuan, Yang
Zhu, Meng
Hu, Wenchao
Liu, Ning
Xing, Dongming
author_sort Chen, Wujun
collection PubMed
description Atherosclerosis is one of the leading causes of disease and death worldwide. The identification of new therapeutic targets and agents is critical. JAZF1 is expressed in many tissues and is found at particularly high levels in adipose tissue (AT). JAZF1 suppresses inflammation (including IL-1β, IL-4, IL-6, IL-8, IL-10, TNFα, IFN-γ, IAR-20, COL3A1, laminin, and MCP-1) by reducing NF-κB pathway activation and AT immune cell infiltration. JAZF1 reduces lipid accumulation by regulating the liver X receptor response element (LXRE) of the SREBP-1c promoter, the cAMP-response element (CRE) of HMGCR, and the TR4 axis. LXRE and CRE sites are present in many cytokine and lipid metabolism gene promoters, which suggests that JAZF1 regulates these genes through these sites. NF-κB is the center of the JAZF1-mediated inhibition of the inflammatory response. JAZF1 suppresses NF-κB expression by suppressing TAK1 expression. Interestingly, TAK1 inhibition also decreases lipid accumulation. A dual-targeting strategy of NF-κB and TAK1 could inhibit both inflammation and lipid accumulation. Dual-target compounds (including prodrugs) 1–5 exhibit nanomolar inhibition by targeting NF-κB and TAK1, EGFR, or COX-2. However, the NF-κB suppressing activity of these compounds is relatively low (IC(50) > 300 nM). Compounds 6–14 suppress NF-κB expression with IC(50) values ranging from 1.8 nM to 38.6 nM. HS-276 is a highly selective, orally bioavailable TAK1 inhibitor. Combined structural modifications of compounds using a prodrug strategy may enhance NF-κB inhibition. This review focused on the role and mechanism of JAZF1 in inflammation and lipid accumulation for the identification of new anti-atherosclerotic targets.
format Online
Article
Text
id pubmed-10404878
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Chongqing Medical University
record_format MEDLINE/PubMed
spelling pubmed-104048782023-08-08 New insights into the suppression of inflammation and lipid accumulation by JAZF1 Chen, Wujun Zhong, Yingjie Yuan, Yang Zhu, Meng Hu, Wenchao Liu, Ning Xing, Dongming Genes Dis Review Article Atherosclerosis is one of the leading causes of disease and death worldwide. The identification of new therapeutic targets and agents is critical. JAZF1 is expressed in many tissues and is found at particularly high levels in adipose tissue (AT). JAZF1 suppresses inflammation (including IL-1β, IL-4, IL-6, IL-8, IL-10, TNFα, IFN-γ, IAR-20, COL3A1, laminin, and MCP-1) by reducing NF-κB pathway activation and AT immune cell infiltration. JAZF1 reduces lipid accumulation by regulating the liver X receptor response element (LXRE) of the SREBP-1c promoter, the cAMP-response element (CRE) of HMGCR, and the TR4 axis. LXRE and CRE sites are present in many cytokine and lipid metabolism gene promoters, which suggests that JAZF1 regulates these genes through these sites. NF-κB is the center of the JAZF1-mediated inhibition of the inflammatory response. JAZF1 suppresses NF-κB expression by suppressing TAK1 expression. Interestingly, TAK1 inhibition also decreases lipid accumulation. A dual-targeting strategy of NF-κB and TAK1 could inhibit both inflammation and lipid accumulation. Dual-target compounds (including prodrugs) 1–5 exhibit nanomolar inhibition by targeting NF-κB and TAK1, EGFR, or COX-2. However, the NF-κB suppressing activity of these compounds is relatively low (IC(50) > 300 nM). Compounds 6–14 suppress NF-κB expression with IC(50) values ranging from 1.8 nM to 38.6 nM. HS-276 is a highly selective, orally bioavailable TAK1 inhibitor. Combined structural modifications of compounds using a prodrug strategy may enhance NF-κB inhibition. This review focused on the role and mechanism of JAZF1 in inflammation and lipid accumulation for the identification of new anti-atherosclerotic targets. Chongqing Medical University 2022-12-02 /pmc/articles/PMC10404878/ /pubmed/37554201 http://dx.doi.org/10.1016/j.gendis.2022.10.029 Text en © 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Chen, Wujun
Zhong, Yingjie
Yuan, Yang
Zhu, Meng
Hu, Wenchao
Liu, Ning
Xing, Dongming
New insights into the suppression of inflammation and lipid accumulation by JAZF1
title New insights into the suppression of inflammation and lipid accumulation by JAZF1
title_full New insights into the suppression of inflammation and lipid accumulation by JAZF1
title_fullStr New insights into the suppression of inflammation and lipid accumulation by JAZF1
title_full_unstemmed New insights into the suppression of inflammation and lipid accumulation by JAZF1
title_short New insights into the suppression of inflammation and lipid accumulation by JAZF1
title_sort new insights into the suppression of inflammation and lipid accumulation by jazf1
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404878/
https://www.ncbi.nlm.nih.gov/pubmed/37554201
http://dx.doi.org/10.1016/j.gendis.2022.10.029
work_keys_str_mv AT chenwujun newinsightsintothesuppressionofinflammationandlipidaccumulationbyjazf1
AT zhongyingjie newinsightsintothesuppressionofinflammationandlipidaccumulationbyjazf1
AT yuanyang newinsightsintothesuppressionofinflammationandlipidaccumulationbyjazf1
AT zhumeng newinsightsintothesuppressionofinflammationandlipidaccumulationbyjazf1
AT huwenchao newinsightsintothesuppressionofinflammationandlipidaccumulationbyjazf1
AT liuning newinsightsintothesuppressionofinflammationandlipidaccumulationbyjazf1
AT xingdongming newinsightsintothesuppressionofinflammationandlipidaccumulationbyjazf1